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Background The European Society of Cardiology (ESC) has published guidelines for the
investigation of patients with suspected heart failure and, if the diagnosis is proven,
their subsequent management. Hospitalisation provides a key point of care at which
time diagnosis and treatment may be refined to improve outcome for a group of
patients with a high morbidity and mortality. However, little international data
exists to describe the features and management of such patients. Accordingly, the
EuroHeart Failure survey was conducted to ascertain if appropriate tests were being
performed with which to confirm or refute a diagnosis of heart failure and how this
influenced subsequent management.
Methods The survey screened consecutive deaths and discharges during 2000–2001
predominantly from medical wards over a 6-week period in 115 hospitals from 24
countries belonging to the ESC, to identify patients with known or suspected heart
failure.
Results A total of 46,788 deaths and discharges were screened from which 11,327
(24%) patients were enrolled with suspected or confirmed heart failure. Forty-seven
percent of those enrolled were women. Fifty-one percent of women and 30% of men
were aged >75 years. Eighty-three percent of patients had a diagnosis of heart failure
made on or prior to the index admission. Heart failure was the principal reason for
admission in 40%. The great majority of patients (>90%) had had an ECG, chest X-ray,
haemoglobin and electrolytes measured as recommended in ESC guidelines, but only
66% had ever had an echocardiogram. Left ventricular ejection fraction had been
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measured in 57% of men and 41% of women, usually by echocardiography (84%) and
was <40% in 51% of men but only in 28% of women. Forty-five percent of women and
22% of men were reported to have normal left ventricular systolic function by
qualitative echocardiographic assessment. A substantial proportion of patients had
alternative explanations for heart failure other than left ventricular systolic or
diastolic dysfunction, including valve disease. Within 12 weeks of discharge, 24% of
patients had been readmitted. A total of 1408 of 10,434 (13.5%) patients died between
admission and 12 weeks follow-up.
Conclusions Known or suspected heart failure comprises a large proportion of
admissions to medical wards and such patients are at high risk of early readmission and
death. Many of the basic investigations recommended by the ESC were usually carried
out, although it is not clear whether this was by design or part of a general routine for
all patients being admitted regardless of diagnosis. The investigation most specific for
patients with suspected heart failure (echocardiography) was performed less fre-
quently, suggesting that the diagnosis of heart failure is still relatively neglected.
Most men but a minority of women who underwent investigation of cardiac function
had evidence of moderate or severe left ventricular dysfunction, the main target
of current advances in the treatment of heart failure. Considerable diagnostic
uncertainty remains for many patients with suspected heart failure, even after
echocardiography, which must be resolved in order to target existing and new
therapies and services effectively.
© 2003 Published by Elsevier Science Ltd on behalf of The European Society of
Cardiology.
Introduction
Heart failure is a major cause of serious morbidity
and death in the population and one of the leading
medical causes of hospitalisation among people
aged greater than 60 years.1–4 The burden of dis-
ease and the resources required to manage it are
likely to escalate over the coming decades for
several reasons.4,5 Probably, the most important
reason is the increasing number of older people in
the population, a group at high risk of developing
heart failure. Paradoxically, improvement in the
treatment of hypertension and myocardial infarc-
tion, although delaying the onset of heart failure,
may increase its incidence and prevalence further.
Furthermore, deployment of effective treatments
for heart failure will increase its prevalence by
extending life.3 A clear understanding of the health
and social challenge set by heart failure is thus of
considerable interest for the community and health
services. However, there are serious gaps in our
knowledge.
Clinical trials provide important, detailed infor-
mation on the natural history of highly selected
groups of patients with heart failure. Although
randomised controlled trials frequently recruit
patients on an international basis, there is a rela-
tive paucity of comparative international epi-
demiological data. It is important, for the proper
interpretation of clinical trials, to have some
measure of the population from which the patients
were drawn. Epidemiological studies often provide
detailed information, however, on a relatively
small number of patients.6–8 Hospital discharge and
health service statistics provide data on large
numbers of patients but limited data on the
accuracy of the diagnosis of heart failure or on
conditions other than the principle diagnosis.3,9,10
There is also evidence of substantial miscoding of
such databases, which underestimates rather than
overestimates the true prevalence of heart fail-
ure.9 Clinical trials, epidemiological databases and
hospital discharge statistics provide little informa-
tion on how patients with suspected heart failure
present to hospital, how it is investigated or what
the outcomes of investigation are.
Guidelines of the European Society of Cardiology
(ESC) that provided recommendations for the
investigation and treatment of heart failure were
published between 1995 and 199711,12 and updated
recently.13 However, it is unclear if the guidelines
are commonly followed in representative popula-
tions of patients with suspected heart failure. The
majority of first presentations of heart failure
occur in hospital and over 40% of patients in the
community with heart failure have been hospital-
ised within the previous year.14,15 Hospitalisation is
a key event that provides an opportunity to clarify
the diagnosis and optimise therapy. Accordingly,
the EuroHeart Failure survey was devised and
conducted, as part of the EuroHeart Survey pro-
gramme, in order to determine whether consecu-
tive patients with known or suspected heart failure
during a hospital admission were being investigated
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and treated in accordance with ESC guidelines.16
The survey also provided an opportunity to obtain
international comparative data on the characteris-
tics and outcome of patients with heart failure,
selected mainly by their need for hospitalisation.
Methods
The design and execution of the survey have been
reported in detail previously.16 The protocol was
approved by the multicentre research ethics com-
mittee (Northern and Yorkshire) in the UK and at
other participating hospitals as required by local
rules.
Clusters of hospitals were formed that generally
included one University hospital and one or more
community hospitals in order to obtain a more
representative sample of hospital deaths and dis-
charges. Each hospital recorded consecutive deaths
and discharges from general medical, cardiology,
cardiac surgery and care of the elderly wards over a
period of 6 weeks and indicated any patient who
had a discharge diagnosis of acute myocardial
infarction, new onset atrial fibrillation or who had
diabetes, in order to gain insights into the popula-
tion screened. Wards solely devoted to other types
of surgery and specialities such as gynaecology and
ophthalmology were excluded. Renal wards were
also excluded since this group of patients often
receive loop diuretic therapy for reasons other than
heart failure. Large hospitals that had more than
150 deaths and discharges per week from relevant
wards were asked to screen wards in rotation each
for a shorter period.16 Screening took place
between the third quarter of 2000 and the second
quarter of 2001.
The case notes of consecutive deaths and
discharges from each patient were reviewed to
identify if the patient fulfilled one or more of the
following four criteria:
1. A clinical diagnosis of heart failure recorded
during the admission (regardless of the primary
reason for admission).
2. A diagnosis of heart failure recorded in the
hospital notes at any time in the last 3 years.
3. Administration of a loop diuretic for any reason
other than renal failure during the 24 h prior to
death or discharge.
4. Administration of treatment for heart failure or
major ventricular dysfunction within 24 h of
death or discharge (investigators were asked, in
particular, to review any prescription of ACE
inhibitor, beta-blocker, diuretics, digitalis
glycosides or spironolactone to determine the
reason for their administration).
The diagnosis was that reported routinely by
clinicians looking after the patient rather than by
the survey investigators. All patients who fulfilled
one or more of these criteria had a detailed record
of the events precipitating their admission, cardio-
vascular investigation, cardiovascular and non-
cardiovascular disease and therapy completed by
an investigator at each site. Surviving patients were
contacted and asked to attend an interview at
12 weeks, at which time any further clinical events,
investigations and treatment were recorded and a
brief examination performed.
The study design attempted to achieve two
fundamental goals. First, to achieve precision (lack
of random error), and second, to achieve validity
(lack of systematic error). Large sample sizes pro-
vide substantial protection from random error. In
the binomial distribution, a probability of an event
or observation of 0.5 is achieved with the greatest
measurement error, which decreases in observa-
tions that move towards a probability of 0 or 1.
Taking a probability of 0.5 as the ‘worst case’, the
95% confidence intervals around an observation, in
a dataset containing 10,000 patients would be
±1.0%. For individual countries providing 500 obser-
vations, the 95% confidence interval would be
±4.4%. Thus, as designed, the study provides statis-
tically precise answers at every level. Screening of
consecutive patients provides some protection
from systematic error, especially where countries
complied with the request to form geographic
clusters. In some countries, only large cardiology
centres participated and data from these countries
may not be representative of the general
population.
Most statistical analyses planned and performed
were simply descriptive, many involving subsets
of patients defined by specific characteristics.
Generalised linear modelling, using a logit link and
binomial error, was used to identify any patient
characteristics that influenced the use of echocar-
diography. A non-linear, mixed, hierarchical ap-
proach to data modelling was used accounting for
hospital clusters. All analyses were conducted using
SAS version 8.1 (Cary NC, SAS Institute 2002).
Results
Nature of participating hospitals (Table 1)
Altogether, 115 hospitals participated, formed into
60 clusters in 24 countries belonging to the ESC
(Table 1). Fifty-eight (50%) hospitals were classi-
fied as University hospitals, 42 (36%) as regional
cardiothoracic centres and 89 (77%) as community
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Table 1 Patients screened and criteria fulfilled for enrolment into the EuroHeart Failure survey
Region/
country
Clusters Hospitals Heart
failure
service
Screening Total patients
enrolled
Enrolment criteria
(more than one may apply)
Patients
screened
Acute MI
(%)
New AF
(%)
Diabetes (%) Nonea Heart failure
diagnosis (%)
Therapy for heart
failure or LV
dysfunction (%)
All Enrolled All Enrolled All Enrolled All Enrolled Number and
% of screened
Current Prior or
current
Loop
diuretic
Other
Northern Europe
UK 10 18 10 8581 6 9 7 14 9 16 81 66 1991/23% 54 70 88 55
Ireland 2 4 2 1146 4 9 5 14 7 11 85 70 278/24% 63 74 90 66
Finland 2 4 3 1179 12 18 10 18 16 23 67 51 569/48% 59 80 85 81
Sweden 2 4 3 1758 8 11 7 14 14 19 74 61 560/32% 59 76 93 76
Denmark 1 1 1 945 3 8 7 14 7 14 85 68 203/22% 53 78 86 69
Western Europe
Austria 1 3 2 1486 3 8 6 12 14 25 80 64 347/23% 95 96 64 94
Germany 5 7 4 2167 6 8 10 13 17 26 71 58 747/35% 89 93 58 88
Switzerland 2 3 1 980 2 6 1 4 11 17 87 76 172/18% 76 89 61 79
Netherlands 1 2 2 599 7 13 8 17 15 25 72 54 101/17% 64 90 79 80
Belgium 1 1 1 44 9 11 30 36 18 22 50 39 44/100% 92 100 78 94
France 3 6 1 2303 2 9 4 21 8 14 88 63 319/14% 63 87 67 64
Central Europe
Czech
Republic
3 6 3 2365 7 8 4 7 22 29 70 61 588/25% 66 89 75 90
Slovak
Republic
1 4 2 779 3 7 6 13 17 20 75 63 256/33% 83 94 64 91
Hungary 3 5 5 980 3 5 6 13 10 17 82 69 260/26% 78 84 90 66
Slovenia 1 3 1 1349 6 10 12 18 18 21 66 57 459/34% 79 87 72 87
Poland 4 8 4 3451 4 6 7 11 13 20 78 65 943/27% 89 93 55 77
Lithuania 1 2 1 643 9 9 20 34 9 8 65 56 229/36% w100 w100 61 87
Russia 2 3 3 1695 8 14 5 8 6 11 83 71 466/28% 98 99 49 81
Mediterranean
Georgia 1 2 1 1302 6 20 3 18 10 11 84 63 187/14% 100 100 81 91
Israel 2 4 1 2460 4 8 3 9 12 29 84 59 604/25% 65 81 92 82
Greece 2 9 3 3449 8 11 6 12 11 20 78 63 422/12% 59 81 93 87
Italy 4 6 3 3347 7 12 4 8 10 17 83 67 589/18% 65 80 81 59
Spain 4 7 3 2662 5 8 6 19 16 25 75 55 642/24% 72 80 88 68
Portugal 2 3 0 1118 8 8 4 10 17 20 73 67 351/31% 73 74 92 77
Overall 60 115 63 46,788 6 10 6 13 12 20 78 62 11,327/24% 71 83 78 75
MI, myocardial infarction; AF, atrial fibrillation.
Note acute MI, AF and diabetes are not mutually exclusive categories.
aNone=no AMI, no AF and no diabetes.
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hospitals, admitting unselected patients directly
from the community. Many hospitals fulfilled all
three functions. Forty-five hospitals served solely
as community hospitals. Fifty-five percent of the
participating hospitals indicated that they had
some form of heart failure service.
Screening (Table 1)
Over 6 weeks, 46,788 deaths and discharges were
recorded; an average of 68 per hospital per week.
Of these patients 6% had had an acute myocardial
infarction, 6% had new-onset atrial fibrillation and
12% had diabetes. Patients with these diagnoses
were about twice as likely to be enrolled with
suspected heart failure.
Enrolment (Table 1)
Overall, 24% of patients were enrolled; an average
of 16 per hospital per week. Eighty-three percent of
patients had a prior or new diagnosis of heart
failure recorded in their notes by the clinician
during his routine practice. Fifty-six percent of
patients had had a diagnosis of heart failure
recorded in their notes at some time in the 3 years
prior to their index admission, while an additional
27% had heart failure recorded for the first time
during the index admission. Seventy-eight percent
of patients were taking a loop diuretic, but this was
the sole criterion for enrolment in only 10%.
Seventy-five percent of patients were taking some
other treatment for heart failure or ventricular
dysfunction but this was the sole criterion for
enrolment in only 2% of patients.
Characteristics of enrolled patients
(Table 2)
The mean age of patients was 71 years. The mean
age of patients was <70 years in most central and
eastern European countries and almost a decade
younger than were those from northern Europe. A
mean age of <70 years in some western European
countries (e.g. Germany, Netherlands) may have
reflected incomplete screening amongst older
patients from general medical wards or the
specialised nature of some hospitals.
About half of patients were women, with little
international variation. A higher proportion of
women (51%) compared to men (30%) were aged
>75 years.
Fifty-six percent of patients had been prescribed
a diuretic for heart failure prior to admission, with
a median duration of treatment of 1.4 years. Forty-
four percent of patients had had a prior hospital-
isation with heart failure. There was evidence
of heart failure prior to admission (prescription of
diuretic for heart failure or a stated diagnosis of
heart failure) in 65% of the patients enrolled,
slightly more than those who had had a prior diag-
nosis of heart failure recorded in their notes (56%).
Overall, 50% of patients were admitted to
general medical and 43% to cardiology wards.
However, there were marked variations between
countries. Despite the age of the population few
were admitted to units specialising in the care of
the elderly, reflecting the lack of development of
such services in many countries and possibly some
selection in screening.
Heart failure was considered to be the primary
reason for admission in 40%, to have complicated or
prolonged stay in a further 17% and to be an inci-
dental finding in 4%. In 26% of patients, heart
failure (past or current) was reported to be the
reason for enrolment but was not assigned to one of
the above categories. In 13% of cases this question
was not answered and the patients were not
enrolled with a diagnosis (past or current) of heart
failure.
Reasons for admission to hospital (Table 3)
The primary and contributory reasons for admission
to hospital were diverse but predominantly cardio-
vascular in nature. Heart failure, cardiac chest pain
and arrhythmias accounted for 59% of the primary
reasons for admission. There was some inter-
national variation partly due to the special inter-
ests of some hospitals (e.g. arrhythmias for the
hospital centre in Lithuania). Hypertension was
reported to be a more common contributor to
admission in central Europe, while syncope and
stroke appeared more common in those countries
where the mean age of patients was highest.
Respiratory infection made an important contri-
bution to admissions in some countries but not
others, but this may have reflected differences in
application of the entry criteria.
Cardiovascular status at the time of
admission to hospital (Fig. 1)
Almost 40% of patients presented with acute
breathlessness while an additional 35% presented
with some other manifestation of worsening heart
failure, such as increasing oedema or exertional
breathlessness. Heart failure was considered stable
in 23% of patients and so presumably was frequently
not the primary reason for admission of these cases.
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Table 2 Patient demographics, speciality at admission and importance of contribution of heart failure to admission
Na Women
(%)
Age
(yrs)
Men >75
years
(%)
Women >75
years (%)
Evidence for heart failure
prior to index admission (%)
Duration
of diuretic
therapy
for HFb
(years)
Duration
of index
hospital
admission
(days)
Speciality at any time during
admission (%)
Contribution of heart
failure to index
admission
Diuretics
for HF
Prior HF
admission
Either GIM Geriatrics Cardiologist Primary
(%)
Secondary
(%)
Northern Europe
UK 1700 52 75 43 60 60 37 64 2.3 12 62 20 21 22 18
Ireland 253 49 71 30 48 58 34 63 1.0 14 52 2 47 25 14
Finland 569 57 75 38 67 50 35 59 1.4 9 48 6 46 31 28
Sweden 553 53 77 52 72 67 46 70 2.6 12 71 9 33 34 8
Denmark 196 53 73 38 51 64 43 67 1.1 8 51 12 36 35 6
Western Europe
Austria 335 50 73 35 63 58 53 89 1.4 13 52 1 38 65 5
Germany 702 35 67 12 36 59 37 68 0.7 10 21 0 70 50 12
Switzerland 171 57 74 46 61 77 66 87 1.5 10 88 0 16 23 23
Netherlands 101 43 68 28 47 62 53 71 3.1 17 33 0 58 15 44
Belgium 41 37 70 35 47 76 51 83 1.4 18 5 0 88 78 7
France 317 59 72 34 64 62 50 68 0.4 10 7 8 83 55 8
Central Europe
Czech
Republic
562 41 69 26 47 58 52 69 1.1 10 62 0 40 53 18
Slovak
Republic
254 43 70 26 53 53 54 69 1.3 14 44 21 35 48 22
Hungary 255 36 63 13 30 60 58 71 0.3 11 8 0 82 54 6
Slovenia 454 49 71 30 51 65 47 69 2.1 10 49 0 53 48 10
Poland 936 50 68 20 37 31 32 42 0.6 14 48 0 51 31 17
Lithuania 226 54 67 19 34 26 78 82 0.6 11 45 0 55 12 24
Russia 370 44 65 13 30 61 69 73 1.2 19 44 0 52 46 41
Mediterranean
Georgia 187 49 65 8 13 21 26 35 1.7 7 12 2 87 75 23
Israel 584 43 75 48 61 71 42 75 0.4 7 90 1 13 38 14
Greece 410 32 68 22 43 74 45 77 2.1 8 23 0 69 59 17
Italy 545 43 70 22 45 63 56 73 0.8 11 30 <1 52 44 12
Spain 633 47 73 38 53 53 42 61 1.1 11 60 6 26 39 25
Portugal 347 52 71 28 48 47 15 50 0.7 11 78 0 37 46 8
Overall 10,701 47 71 30 51 56 44 65 1.4 11 50 5 43 40 17
aOnly patients enrolled and with data returned and entered on the database are included leading to minor differences in numbers enrolled between Tables 1 and 2.
bMedian excluding patients with no such report prior to index admission.
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Table 3 Reasons for index hospital admission in the population enrolled
1=Primary reason Heart
failure %
Cardiac
chest
pain %
Arrhythmias
%
Hypertension
%
Syncope/
dizziness
%
Stroke/
neuro.
%
CVS
surgery
and
devices %
Other CVS
%
Cancer % Gastro-
intestinal
%
Respiratory
%
Other %
1 Any 1 Any 1 Any 1 Any 1 Any 1 Any 1 Any 1 Any 1 Any 1 Any 1 Any 1 Any
Northern Europe
UK 20 48 23 32 7 22 <1 4 3 6 3 5 6 8 2 5 2 4 4 7 15 23 15 30
Ireland 24 61 18 28 7 20 1 12 4 6 4 8 2 8 1 9 2 3 2 6 19 42 13 36
Finland 26 54 24 29 9 21 <1 8 1 4 2 5 4 8 4 14 1 3 4 6 6 14 18 35
Sweden 27 57 23 29 6 25 1 11 2 4 7 9 <1 3 2 10 1 4 2 5 14 26 14 41
Denmark 22 42 22 27 6 8 1 1 3 3 0 1 4 7 3 6 2 4 2 4 16 25 18 27
Western Europe
Austria 39 72 19 21 5 13 3 6 5 8 6 7 5 18 4 9 2 4 3 3 3 8 6 12
Germany 22 60 18 30 9 26 2 28 1 2 1 2 27 42 7 20 1 4 3 4 2 7 6 20
Switzerland 21 77 17 35 5 15 1 19 2 2 2 2 11 16 8 22 1 3 8 10 7 12 16 35
Netherlands 33 54 17 27 9 18 0 2 0 0 0 0 13 17 2 5 3 7 3 4 4 14 16 28
Belgium 73 85 7 12 2 27 0 2 7 10 0 2 0 12 2 15 2 2 0 2 2 10 2 17
France 48 68 7 15 6 31 0 3 2 2 1 2 24 27 4 16 0 4 <1 1 4 12 4 14
Central Europe
Czech Republic 45 78 12 20 5 24 1 17 2 2 4 7 15 28 2 23 1 2 2 7 2 12 8 30
Slovak Republic 33 77 16 33 7 25 4 24 2 5 4 7 8 28 9 21 2 6 4 9 3 10 7 24
Hungary 25 71 10 25 12 32 7 34 1 3 1 2 10 24 13 37 1 2 <1 2 2 8 9 27
Slovenia 41 69 16 28 7 28 2 26 <1 <1 3 5 8 8 4 19 1 3 6 9 6 21 6 34
Poland 28 79 22 45 7 25 3 30 3 5 4 6 5 17 10 21 2 3 4 7 7 15 7 19
Lithuania 8 98 38 65 21 40 10 42 2 3 0 <1 9 19 8 12 <1 1 <1 2 3 5 <1 7
Russia 49 92 28 50 5 28 9 47 1 3 0 1 1 8 2 14 0 1 0 0 3 4 2 9
Mediterranean
Georgia 65 100 27 39 2 32 3 50 0 0 0 3 0 1 3 27 0 1 0 3 0 14 0 11
Israel 33 56 26 37 6 18 1 8 3 4 1 2 3 7 1 5 2 4 2 5 4 9 19 34
Greece 49 76 18 27 6 20 1 9 <1 2 1 1 17 30 2 9 0 2 1 2 1 5 2 11
Italy 36 68 20 30 8 21 1 15 1 2 1 2 14 28 3 15 3 4 2 3 7 16 3 19
Spain 32 62 14 19 3 20 1 17 1 1 3 4 2 4 3 12 1 4 3 6 26 43 9 29
Portugal 38 73 14 32 6 27 1 24 1 2 3 5 17 22 1 13 2 5 3 5 6 28 7 23
Overall 32 66 20 31 7 23 2 17 2 3 3 4 9 16 4 14 1 3 3 5 8 17 10 25
1=heart failure was reported as the most important reason for admission. Any=heart failure was reported either as the most important reason for admission or as a second or third
diagnosis. Note that heart failure may not have been present on admission but could be the patients' most important problem during admission. Neuro, neurological; CVS,
cardiovascular.
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Nineteen percent presented with an acute coronary
syndrome, 9% with rapid atrial fibrillation and 2%
with a ventricular arrhythmia. Less than 1% pre-
sented with a cardiac arrest or cardiogenic shock.
In 15% of patients, heart failure was not evident at
the time of admission. Within this sub-group, 14%
were reported to have developed heart failure
during admission and 2% were reported to have
asymptomatic cardiac dysfunction.
Investigations (Tables 4 and 5)
Ninety-five percent of patients were reported to
have had an ECG. ECGs are being analysed in a
central laboratory and will be the subject of a
future report. A preliminary report indicates that
only 3% of ECGs appeared normal, although a fur-
ther 39% exhibited only minor abnormalities.17 A
chest X-ray report was available for 92% of patients
and in 71% of these cases cardiomegaly, pulmonary
congestion or both were reported (Fig. 2). Other
investigations, which guidelines on heart failure
suggest should be routine, including haemoglobin,
electrolytes and renal function, were measured in
>90% of patients.
Sixty-three percent of patients had a left
ventricular ejection fraction reported by at least
one imaging test, most often echocardiography.
When measured, LVEF was <40% in only 45% of cases
(Fig. 3). There was substantial international varia-
tion in the use of echocardiography, with patients
in northern Europe being generally less likely to be
investigated. Amongst the 66% of patients who
were reported to have had an echocardiogram,
moderate or severe left ventricular systolic dys-
function was reported in only 46% and was more
common among men (61%) than among women
(35%) (Fig. 4a,b). However, left ventricular dia-
stolic function was seldom reported. Twenty-nine
percent of patients were reported to have moder-
ate to severe mitral regurgitation, while 16% of
patients were reported to have moderate to severe
pulmonary hypertension.
In a multivariate model in patients with a
measurement of left ventricular function, the like-
lihood of a patient having evidence of moderate or
severe left ventricular systolic dysfunction was less
if they were aged ≥70 years (odds ratio 0.76, 95% CI
0.68–0.85) or had respiratory disease (odds ratio
0.74, 95% CI 0.66–0.84). Independently, male
gender (odds ratio 2.84, 95% CI 2.57–3.18), previ-
ous admission for heart failure (odds ratio 1.84, 95%
CI 1.62–2.08), diuretic therapy (odds ratio 1.39,
95% CI 1.24–1.55) and ischaemic heart disease
(odds ratio 1.27, 95% CI 1.12–1.43) were associated
with the presence of moderate to severe left
ventricular systolic dysfunction.
Other investigations that may be considered in
patients with heart failure but are not recom-
mended as a routine in the guidelines were con-
ducted less frequently than those mentioned
earlier in most countries. Coronary arteriography,
exercise testing and pulmonary function tests were
conducted on a substantial minority of patients.
Stress-imaging tests for myocardial ischaemia and
viability and exercise testing with metabolic gas
exchange were rarely performed. There was
Fig. 1 Cardiovascular status at the time of admission for patients enrolled in the EuroHeart Failure survey. More than one status may
apply at the time of admission. MI, myocardial infarction.
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Table 4 Percentage of patients undergoing investigations in the enrolled population (index=this admission, total=this admission, prior admission or subsequent data)
ECG CXR Echo Haemoglobin Electrolytes Pulmonary
function
Exercise test Peak oxygen
uptake
Stress imaging Coronary
angiogram
Index Total Index Total Index Total Index Total Index Total Index Total Index Total Index Total Index Total Index Total
Northern Europe
UK 89 91 74 93 12 56 93 96 96 97 3 14 2 13 <1 1 <1 4 4 19
Ireland 91 94 87 96 18 63 97 98 99 100 9 19 7 22 <1 1 1 4 9 34
Finland 91 94 85 98 29 53 95 87 96 98 11 29 6 22 1 2 <1 3 14 29
Sweden 88 91 69 92 26 68 95 99 98 98 3 13 4 20 <1 1 1 3 5 18
Denmark 91 93 61 83 17 41 97 99 97 99 4 10 4 13 0 0 1 3 8 23
Western Europe
Austria 96 99 97 100 48 80 98 99 99 100 14 22 3 14 1 2 <1 5 26 41
Germany 99 99 57 83 37 88 97 97 97 98 19 34 17 44 2 5 2 8 60 86
Switzerland 95 97 88 95 20 55 100 100 97 98 7 24 6 23 1 2 3 7 15 29
Netherlands 94 97 85 99 27 94 96 98 96 99 14 53 7 29 0 4 1 21 12 45
Belgiuma 100 100 90 93 73 90 100 100 100 100 7 27 7 17 7 17 24 39 15 54
France 95 96 91 93 57 93 96 96 97 98 11 20 13 20 5 7 4 8 31 60
Central Europe
Czech Republic 96 97 76 92 54 76 95 98 96 98 17 29 9 21 7 12 1 3 12 32
Slovak Republic 99 100 92 98 74 84 98 99 98 99 28 39 7 17 0 0 0 <1 28 33
Hungary 98 98 82 86 35 83 93 93 91 92 7 19 12 22 4 6 5 10 25 40
Slovenia 97 97 87 95 33 62 89 90 99 99 6 11 2 13 <1 1 1 3 14 23
Poland 97 97 67 88 46 63 96 96 97 98 4 7 6 12 <1 1 2 3 20 29
Lithuaniaa 94 100 78 100 66 90 99 99 65 65 <1 30 12 31 <1 <1 <1 6 11 22
Russia 96 97 89 93 54 59 96 98 60 62 7 9 10 14 0 0 4 4 7 15
Mediterranean
Georgia 100 100 92 93 68 81 99 100 81 87 1 1 29 31 0 0 1 1 1 1
Israel 85 86 88 91 7 47 97 97 97 98 1 1 1 1 1 1 1 4 5 34
Greece 99 100 89 93 35 80 93 93 92 94 11 25 8 32 7 16 8 23 16 59
Italy 96 98 65 75 49 73 98 98 99 99 4 9 6 17 <1 1 5 15 25 42
Spain 93 95 96 99 29 62 97 99 96 98 8 23 2 7 <1 1 2 4 8 21
Portugal 91 95 79 87 37 48 96 96 97 97 1 1 0 0 0 0 1 1 7 17
Overall 94 95 79 92 34 66 96 97 94 95 8 17 7 17 1 3 2 6 16 32
aNo follow-up data were received from Belgium and Lithuania. These data are based solely on data acquired during the index admission.
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Table 5 Results of diagnostic imaging
Left ventricular
ejection fraction
measured
Method for measuring left
ventricular ejection fraction
(%)a
Moderate or severe on echocardiography (%)b
Ever Within
1 year
Echo RNVG Angio Other Left ventricular Left
atrial
dilatation
Valve
stenosis
Valve
regurgitation
Right
ventricular
dysfunction
Pulmonary
hypertension
Systolic Diastolic Dilatation Mitral Aortic Mitral Aortic
Northern Europe
UK 40 30 86 8 3 3 34 7 14 11 2 4 19 6 3 3
Ireland 51 43 92 1 0 7 36 35 26 28 2 6 27 9 9 4
Finland 56 49 91 3 3 3 33 8 21 26 2 9 29 8 7 13
Sweden 67 48 93 0 0 7 41 6 19 30 2 8 35 8 5 26
Denmark 43 36 82 1 6 11 32 3 30 4 1 4 8 1 4 7
Western Europe
Austria 80 74 93 2 2 3 52 9 30 51 3 10 42 11 1 23
Germany 87 83 51 19 26 4 60 24 31 42 2 8 25 5 6 23
Switzerland 61 47 80 18 0 2 52 12 13 23 2 10 20 8 5 27
Netherlands 72 53 75 10 4 11 60 8 30 32 11 15 33 11 3 6
Belgiumc 93 90 79 0 11 11 49 30 43 41 5 8 41 3 14 46
France 91 84 85 <1 13 2 57 6 36 39 <1 10 39 11 10 32
Central Europe
Czech
Republic
79 73 94 1 4 1 60 6 29 26 2 5 38 5 11 18
Slovak
Republic
83 80 94 0 3 3 42 15 11 33 4 11 18 6 6 19
Hungary 66 56 80 0 6 14 50 20 48 36 2 9 41 11 2 22
Slovenia 60 52 85 <1 5 10 41 5 27 51 2 10 59 16 1 18
Poland 60 57 89 <1 6 5 47 16 32 32 4 6 27 7 7 6
Lithuaniac 90 81 98 0 0 2 63 39 19 63 2 4 37 5 16 18
Russia 58 58 91 1 5 3 56 17 44 29 6 4 41 8 16 19
Mediterranean
Georgia 81 81 92 0 0 8 30 5 31 31 1 0 7 2 1 0
Israel 30 16 52 3 5 40 25 3 7 8 3 8 18 4 3 10
Greece 86 79 69 16 10 5 65 16 51 48 3 8 29 8 12 21
Italy 72 68 93 1 4 2 45 11 23 21 4 3 24 6 4 18
Spain 62 49 85 3 8 4 37 7 19 26 9 10 26 11 4 26
Portugal 52 48 90 3 0 7 Data not completed
Overall 63 55 84 4 6 5 46 12 26 31 3 7 29 7 6 16
aData shown are the percentages undergoing measurement of left ventricular ejection fraction.
bData shown are the percentages of those who underwent echocardiography (see Table 4).
cNo follow-up data were received from Belgium and Lithuania. These data are based solely on data acquired during the index admission.
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evidence of considerable international variation in
the use of coronary arteriography, with the major-
ity of patients enrolled in Germany, France and
Greece undergoing this procedure.
Aetiology of heart failure (Table 6)
Ischaemic heart disease, identified from the
patients' history or by coronary angiography, was
Fig. 2 Radiological evidence for heart failure on or after the index admission for patients enrolled in the EuroHeart Failure survey.
Fig. 3 Distribution of left ventricular ejection fraction measured within 12 months of the survey amongst women (n2048; 41% of
total enrolled) and men (n3249; 57% of total enrolled) enrolled in the EuroHeart Failure survey. Where more than one ejection
fraction measurement was available, the most recent one was used. Fifty-one percent of men but only 28% of women had a left
ventricular ejection fraction <40%.
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the commonest potential cause of heart failure in
all countries apart from France, Spain, Portugal and
Hungary. However, one-third of patients with
ischaemic heart disease were not reported to have
had a myocardial infarction. Moderate or severe
valve disease on echocardiography or prior severe
valve disease as evidenced by valve surgery was
reported to have contributed to the development
of heart failure in 29% of patients, the most com-
mon lesion being secondary mitral regurgitation.
Dilated cardiomyopathy was a stated diagnosis in
11% of patients but almost half were also reported
to have coronary artery disease or hypertension and
only 6% had this as the sole diagnosis. Dilated
cardiomyopathy appeared more common in France
and Hungary.
Concomitant cardiovascular disease and risk
factors (Table 7)
Expected risk factors for cardiovascular disease
were prevalent amongst the patients in this survey;
53% had hypertension and 27% had diabetes. Some
international variation was observed but without a
consistent regional pattern. A total of 3931 patients
(35%) were reported to have had a serum choles-
terol measured, which was reported to be
≥5.0 mmol/l in 50%. Twenty percent of patients
were taking lipid lowering therapy. Atrial (43%)
and ventricular (8%) arrhythmias were commonly
identified in this population. In addition, syncope
and blackouts, symptoms that are likely to reflect a
combination of hypotension, cerebral vascular dis-
ease and a variety of arrhythmias, affected 16% of
patients. There was little international variability.
Some countries reported high rates of ventricular
arrhythmias but this may reflect differences in the
frequency with which ambulatory monitoring is
used to detect asymptomatic arrhythmias.
Almost 1000 patients (8% of those enrolled)
had had a pacemaker implanted. Conventional
pacing may cause ventricular dyssynchrony but
few, if any, pacemakers would have been for car-
diac resynchronisation, given the timing of the sur-
vey. Less than 1% of patients had an implantable
defibrillator.
Nine percent of patients were reported to have
had a stroke and 10% a transient ischaemic attack.
Twelve percent of patients were reported to suffer
from dementia or mental confusion, reflecting the
age of the patients. Although some of the mental
confusion may have been due to worsening heart
failure or infection and reversible with treatment,
it is likely that many of these patients would have
major persisting cognitive dysfunction on formal
testing.
Concomitant non-cardiovascular disease
(Table 7)
In addition to diabetes, reported earlier, important
non-cardiovascular problems known to complicate
the management of heart failure were common. A
total of 9971 patients had a value for haemoglobin
reported, which was less than 11 g/dl in 18% of men
and 23% of women (Fig. 5). Renal dysfunction was
reported to have complicated the management of
patients with known or suspected heart failure in
18% of cases. Serum creatinine was reported in
6598 patients and was ≥150 µmol/l in 1059 (16%)
and ≥200 µmol/l in 437 (7%) (Fig. 6). Twenty
percent of patients had a serum sodium
≤135 mmol/l. Thirty-two percent of patients were
reported to have respiratory disease but this is only
likely to be a rough estimate given the lack of
respiratory function testing. Gout and arthritis,
conditions that may not only limit mobility but
may lead to the prescription of non-steroidal
anti-inflammatory drugs that may exacerbate renal
Fig. 4 Distribution of the severity of left ventricular systolic
dysfunction by qualitative assessment in (a) women (n2607;
52% of the total enrolled) and (b) men (n3666; 64% of the total
enrolled) enrolled in the EuroHeart Failure survey. Sixty-one
percent of men but only 35% of women had left ventricular
systolic dysfunction reported as moderate or severe. Forty-five
percent of women but only 22% of men had left ventricular
function reported as normal.
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Table 6 Evidence for ischaemic heart disease, valve disease and dilated cardiomyopathy in the population enrolled (index=this admission, total=this admission, prior admission or
subsequent data)
Myocardial
infarction
History of stable or
unstable angina
Coronary
angiography
Angioplasty CABG Cumulative
evidence
for CAD
Valve surgery or
moderate/severe
valve disease on
echo.
Dilated
cardiomyopathya
Index Prior Total Index Prior Total Index Prior Total Index Prior Total Index Prior Total Total Index Prior Total Index Prior Total
Northern Europe
UK 9 40 41 40 52 56 4 15 19 1 3 4 3 8 10 66 5 12 17 1 2 2
Ireland 9 42 42 36 43 48 9 25 34 4 4 8 0 12 12 60 7 14 24 8 7 10
Finland 18 38 44 26 45 49 14 16 29 5 6 10 3 12 15 66 13 10 24 5 3 5
Sweden 12 40 41 35 42 46 5 13 18 1 3 4 <1 9 10 59 13 17 30 2 2 2
Denmark 12 38 40 31 35 37 8 17 23 4 12 13 2 10 12 52 2 5 7 1 1 1
Western Europe
Austria 4 31 32 43 43 44 26 24 41 6 7 11 1 10 11 53 23 18 41 9 8 10
Germany 8 50 51 57 64 70 60 53 86 14 24 32 9 22 29 82 17 19 35 7 5 8
Switzerland 6 28 28 33 47 50 15 21 29 5 9 12 0 9 9 58 7 12 20 4 1 4
Netherlands 13 54 56 34 52 59 12 36 45 3 14 15 10 24 33 72 17 34 48 3 3 3
Belgiumb 10 56 n.a. 24 54 56 15 41 54 7 10 17 0 22 22 76 44 15 51 3 1 3
France 8 27 29 11 32 33 31 41 60 3 8 10 2 6 8 47 34 22 51 17 15 22
Central Europe
Czech Republic 8 44 45 21 34 36 12 21 32 3 4 7 0 6 6 57 24 10 36 9 9 10
Slovak Republic 7 43 45 56 59 66 28 11 33 5 2 6 4 3 7 77 22 10 31 2 2 2
Hungary 9 31 32 27 35 38 25 21 40 1 2 2 3 6 8 48 25 25 50 17 15 17
Slovenia 8 23 24 38 38 45 14 9 23 3 4 5 1 4 5 51 23 22 45 9 8 11
Poland 6 33 34 62 63 68 20 11 29 3 3 6 2 5 7 71 21 12 31 2 1 3
Lithuaniab 8 33 33 82 79 83 40 47 51 5 4 9 0 6 6 84 28 14 41 3 2 3
Russia 14 52 52 62 58 66 7 9 15 1 2 2 1 3 4 77 27 5 29 4 2 5
Mediterranean
Georgia 16 33 34 51 49 55 1 0 1 0 0 0 0 1 1 57 6 1 7 3 2 3
Israel 9 48 50 54 61 66 5 30 34 3 14 15 4 16 19 76 3 15 18 1 1 1
Greece 10 36 38 21 36 36 16 44 59 2 6 7 6 15 21 55 15 22 37 12 10 12
Italy 11 37 39 36 34 44 25 21 42 8 9 16 5 8 12 57 19 10 27 11 6 11
Spain 8 21 24 16 22 26 8 13 21 1 2 3 1 4 5 37 14 16 28 5 3 5
Portugal 13 19 25 20 16 27 7 11 17 4 5 9 0 7 7 39 4 12 12 0 0 0
Overall 9 38 39 40 47 51 15 20 32 4 6 9 3 9 11 68 16 14 29 5 4 6
CABG, coronary artery bypass grafting; CAD, coronary artery disease.
aOverall, 11% of patients were stated to have dilated cardiomyopathy by the investigators. Numbers shown exclude patients with coronary disease or hypertension.
bNo follow-up data were received from Belgium and Lithuania. These data are solely based on data acquired during index admission.
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Table 7 Concomitant cardiovascular and non-cardiovascular problems in the population enrolled (data shown are percentages)
Hypertension Diabetes AF VT/VF Syncope Devices Stroke TIA Dementiaa Renal
dysfunction
Respiratory
disease
PTE Gout Arthritis Infectionb
Chronic Total Pacing ICD
Northern Europe
UK 47 21 22 42 7 15 6 <1 10 13 14 13 31 4 6 20 28
Ireland 45 16 23 40 9 19 8 2 7 17 17 9 50 4 8 15 45
Finland 47 26 22 44 12 27 8 1 10 16 18 11 24 4 11 8 31
Sweden 39 23 22 41 6 13 7 0 14 16 13 7 27 3 9 5 29
Denmark 22 18 15 33 7 9 8 0 4 8 9 9 35 2 5 5 23
Western Europe
Austria 54 31 21 36 11 8 8 1 13 8 7 29 17 5 3 2 17
Germany 65 35 22 41 12 12 11 1 7 6 6 20 22 2 5 11 19
Switzerland 58 26 22 44 10 23 9 1 6 8 17 36 31 10 5 18 20
Netherlands 35 26 20 50 19 18 14 1 3 8 12 41 33 4 10 4 21
Belgium 59 20 32 66 20 22 22 10 10 2 10 37 27 2 7 2 17
France 51 18 23 56 7 10 14 1 4 10 8 35 26 4 6 3 16
Central Europe
Czech
Republic
59 46 26 38 7 13 11 <1 13 12 10 18 25 6 5 9 16
Slovak
Republic
69 39 24 47 6 24 7 0 15 19 15 30 39 6 23 20 37
Hungary 53 25 22 37 9 11 15 0 5 9 6 6 17 3 4 4 13
Slovenia 50 34 22 51 9 20 5 <1 10 7 17 26 45 4 7 7 28
Poland 58 23 21 40 7 20 8 0 9 7 23 14 32 2 2 17 18
Lithuania 69 12 18 51 4 56 11 0 4 20 4 12 70 4 2 29 11
Russia 67 16 23 43 12 18 3 0 7 5 9 6 24 1 1 6 6
Mediterranean
Georgia 70 14 24 38 33 1 1 0 2 4 0 10 24 0 0 9 15
Israel 58 36 28 42 6 8 7 <1 15 4 10 29 23 1 3 2 29
Greece 55 32 24 41 11 13 13 1 5 6 7 19 20 1 7 7 10
Italy 47 23 21 31 5 10 8 0 3 9 4 12 35 2 2 5 13
Spain 56 37 29 49 3 6 6 <1 8 9 12 21 52 2 3 4 42
Portugal 47 29 32 42 4 10 15 1 10 9 10 16 50 5 1 3 36
Overall 53 27 23 42 8 15 8 <1 9 10 12 17 32 3 5 10 24
AF, atrial fibrillation; VT/VF, ventricular tachycardia or ventricular fibrillation; PTE, pulmonary thromboembolism; ICD, implantable cardiac defibrillator.
aDementia or mental confusion and therefore may not have been irreversible.
bInfection on the index admission only.
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dysfunction and cause sodium retention in patients
with heart failure, were also common. A total of
2617 patients had uric acid levels measured;
plasma concentrations were ≥0.5 mmol/l in 21%.
Clinical outcomes (Table 8)
The average duration of the index admission was 11
days. Amongst 8463 patients who survived the
Fig. 5 Distribution of haemoglobin values recorded in 5249 (92% of total enrolled) of the men enrolled in the EuroHeart Failure
survey.
Fig. 6 Distribution of serum creatinine values recorded in 3144 (62% of total enrolled) of the women enrolled in the EuroHeart Failure
survey. Renal function was recorded using urea or blood urea nitrogen in a large proportion of the remainder.
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Table 8 Outcome
Data
available
Readmissions within 12 weeks Patients readmitted within 12 weeks Deaths
Total For heart
failurea
With heart
failurea
Percentage of
patients
Age Percent who
were female
On index
admission (%)
Total (%) Age (years) Female
(% of total)
Northern Europe
UK 1249 496 84 72 31 75 52 9.1 15.5 79 57
Ireland 203 48 7 11 36 71 53 9.9 14.2 78 49
Finland 458 448 32 40 54 73 59 9.5 17.8 78 59
Sweden 535 328 70 65 41 77 51 2.9 15.0 80 56
Denmark 182 63 6 4 29 73 56 5.6 11.7 79 59
Western Europe
Austria 296 149 34 12 41 73 46 10.2 18.8 78 54
Germany 532 233 22 64 36 66 28 3.9 6.4 74 45
Switzerland 109 27 4 7 28 74 48 9.9 16.4 75 61
Netherlands 94 54 10 2 36 65 38 6.9 13.9 68 80
Belgium No data supplied 4.9 n.a. 52 0
France 249 67 14 3 27 72 27 7.6 15.5 76 45
Central Europe
Czech
Republic
517 175 75 26 31 63 32 6.4 14.4 73 46
Slovak
Republic
215 103 16 15 39 70 37 9.8 20.5 77 53
Hungary 198 57 12 20 21 61 26 3.9 8.6 69 50
Slovenia 408 122 44 32 26 70 45 9.5 14.5 74 47
Poland 835 101 23 40 12 66 49 7.8 10.7 73 50
Lithuania No data supplied 1.3 n.a. 75 100
Russia 362 6 2 1 3 60 44 1.6 4.1 71 40
Mediterranean
Georgia 177 8 4 2 5 64 13 5.4 21.9 66 41
Israel 489 177 37 16 28 74 50 3.8 9.9 80 44
Greece 312 46 24 2 17 65 26 7.3 12.2 74 33
Italy 419 77 23 5 21 69 43 3.5 11.6 72 52
Spain 549 165 48 21 26 72 42 9.6 18.6 79 52
Portugal 75 None reported n.a. n.a. 8.4 10.7 75 45
Overall 8463 2950 591 460 24.2% (2046) 71 45 739/10,701b (6.9%) 1408/10,434b
(13.5%)
76 717 (51%)
aFor heart failure means heart failure coded in the first position/with heart failure means heart failure coded in the second or third position.
bNumber of patients in whom status alive or dead was recorded (98% of enrolled patients for whom baseline data were received.)
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index admission and had 12-week follow-up data,
2950 re-admissions occurred in 2046 patients during
this period (Fig. 7). Heart failure was the principal
cause for readmission in 591 (20.0% of admissions)
and contributed in a further 460 (15.6%). A total of
1413 patients (13%) died between admission and
the 12 week follow-up visit with similar numbers
dying during (Fig. 8) and after the index admission.
There was some international variation in the
index admission mortality and in readmission rates
but 12-week mortality was fairly consistent. Low
12-week mortality in Germany and Hungary may be
related to the relatively young age of patients
enrolled in these two countries.
Patient interview and examination
(Table 9)
A total of 3260 surviving patients (38.5% of those
with 12-week follow-up data) attended the
Fig. 7 Deaths on index admission and discharges from the time of admission for 10,701 patients.
Fig. 8 First admission over 12 weeks for any reason from the time of index admission discharge (n8463).
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Table 9 Results of patient interview and physical examination
N Age Female
(%)
NYHA class % BMI Seated Bilateral
pitting
oedema
Final diagnosis for patients attending interview
I II III/IV <20 >30 Heart
rate
SBP Percent with SBP
>140 mmHg
DBP Definite Probable Possible Doubtful Absent
Northern Europe
UK 332 71 43 22 37 40 5 30 76 135 34 77 31 23 28 22 16 3
Ireland 107 69 44 26 34 39 6 36 77 128 29 79 14 41 23 15 11 6
Finland 227 72 53 37 26 34 4 20 68 137 31 77 18 25 12 15 19 21
Sweden 136 73 38 31 35 34 4 26 70 139 41 79 26 39 17 14 13 13
Denmark 70 69 43 24 37 38 5 20 72 135 34 78 36 33 23 23 13 3
Western Europe
Austria 113 66 32 41 35 25 7 19 73 134 29 73 14 86 7 2 1 4
Germany 342 64 25 25 52 24 3 19 74 135 25 81 19 64 14 15 4 2
Switzerland 68 73 50 60 28 12 10 15 74 124 19 72 37 65 15 3 1 13
Netherlands 37 68 32 51 30 16 0 19 78 129 32 71 27 19 11 24 30 16
Belgium No data supplied
France 26 72 27 54 38 8 4 12 76 137 23 91 8 46 4 4 4 42
Central Europe
Czech Republic 242 64 31 36 42 23 3 28 76 130 31 78 14 60 11 7 1 21
Slovak Republic 138 68 41 30 41 30 3 22 76 140 43 82 28
Hungary 122 60 28 59 21 16 4 34 74 122 18 76 31 56 18 14 8 2
Slovenia 184 70 44 32 45 22 3 32 75 141 48 80 30 54 23 14 5 3
Poland 295 66 50 27 49 24 2 31 80 134 25 79 18 36 26 22 9 6
Lithuania No data supplied
Russia 76 62 29 36 33 31 4 18 76 132 24 79 26 84 7 7 3 0
Mediterranean
Georgia 93 65 44 60 27 13 0 3 79 140 40 83 27 22 10 23 24 23
Israel 67 72 34 43 21 31 6 27 74 129 16 74 28 37 25 21 11 6
Greece 153 63 28 48 32 20 3 19 75 121 14 76 18 67 16 9 5 2
Italy 228 68 39 46 30 22 5 14 75 129 16 78 18 24 17 16 15 26
Spain 168 69 54 35 36 28 3 37 77 137 33 77 27 32 26 18 8 10
Portugal 36 70 47 64 17 14 8 19 66 135 36 77 17 14 14 31 31 6
Overall 3260 68 39 36 37 26 4 24 75 133 29 78 23 44 18 15 10 10
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interview. These patients tended to be younger and
included a higher proportion of men than in the
enrolled population. Most patients attending the
interview had no or only mild symptoms of heart
failure, but a substantial minority had continuing
moderate to severe symptoms and pitting oedema
remained common. A substantial proportion
appeared obese with few patients showing marked
cachexia. Heart rate appeared generally well con-
trolled, but systolic blood pressure remained above
140 mmHg in 29% of patients. The investigator was
asked to state how sure they were that heart failure
was present or absent, in the light of the patient's
history and after the interview and examination.
The diagnosis was considered definitely present in
44% and definitely absent in 10%, indicating a high
level of persisting diagnostic uncertainty in this
patient population. Uncertainty about the diag-
nosis appeared to vary amongst countries. There
appeared to be greater diagnostic uncertainty
when patients were investigated less intensively.
Discussion
The EuroHeart Failure is one of the largest surveys
of its kind, having screened almost 50,000 consecu-
tive hospital deaths and discharges and collected
detailed information on >10,000 patients with a
possible diagnosis of heart failure. The survey pro-
vides a wealth of information for those who care for
patients with heart failure, those who have to
design health services for their population and for
investigators wishing to conduct trials to improve
care.
Diagnosis ‘of’ heart failure
There are many definitions of heart failure.11 The
EuroHeart Failure survey attempted to enrol a
broad range of patients in order to explore the
investigation of patients in whom the diagnosis was
uncertain. The survey was successful in enrolling a
large number of patients with a high probability
of having heart failure. Eighty-three percent of
patients had been given a diagnosis of heart failure
at some time by those caring for them, 97% of
patients had an abnormal ECG,17 71% of patients
had radiological evidence suggestive of heart fail-
ure, 78% were receiving a loop diuretic and 75%
were receiving some other therapy targeted at
heart failure.
Most investigations recommended by the ESC
for the diagnosis of heart failure appear to be
followed with, unfortunately, the exception of an
objective test of cardiac function. It is likely that
the high adherence to ECG, haematology and bio-
chemistry tests reflects the fact that they are part
of the routine clinical practice for all admissions.
The failure to assess cardiac function in a third of
patients, particularly older patients, reflects a
substantial diagnostic deficiency compared to ESC
guidelines. The large international variation in the
use of echocardiography indicates that differ-
ences in the way that care is provided should be
explored. The substantial residual uncertainty in
the diagnosis of heart failure reported by the
investigators at the end of the survey suggests
that further efforts are required to lower the
threshold for cardiac imaging and/or that further
tests, such as for natriuretic peptides, may be
required to reach a definitive diagnosis of heart
failure.18,19 Measurement of natriuretic peptides
on a large proportion of the participants in this
survey is underway.
Diagnosis ‘in’ heart failure
The survey shows the diverse and complex pathol-
ogy underlying heart failure, which not only is part
of the problem in understanding and managing
it but also provides multiple opportunities for tar-
geted interventions. Most patients had coronary
artery disease while dilated cardiomyopathy in the
absence of other obvious causes for heart failure
appeared uncommon in most countries. However,
many patients who had heart failure associated
with coronary disease had not had a myocardial
infarction. Further analysis will be required
to determine to what extent this reflects
misdiagnosis, ischaemia masquerading as heart fail-
ure, failure to diagnose myocardial infarction
(which will be checked by the core laboratory read-
ing of the ECGs) or the presence of myocardial
stunning and hibernation.20 However, cholesterol
was often not measured and was often elevated
when it was. Whether or not treatment of hyper-
lipidaemia is safe or effective in patients with
heart failure is a matter of controversy21,22 and the
subject of several ongoing randomised controlled
trials.
The survey highlights the diversity of cardiac
pathophysiology underlying heart failure. Prior to
the publication of the SOLVD treatment trial23 that
chose to include only patients with an LVEF ≤35%,
trials of heart failure had generally relied on a
clinical diagnosis to enrol patients. The use of LVEF
helped ensure a correct diagnosis and identified a
higher risk sub-sub-set, albeit within a low risk
subset, from which older patients and those with
concomitant disease, both markers of high risk,
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were excluded. The trial showed that the risk in this
sub-sub-population was modifiable and conse-
quently future investigators focussed almost exclu-
sively on such patients until recently. This survey,
and other epidemiological evidence, suggests that
50% or more of patients with a clinical diagnosis of
heart failure have preserved LVSD.24 Patients with
LVSD tend to be younger and male while those with
preserved LV function are often women aged >75
years, accounting for much of the difference
between heart failure in epidemiological studies
and in clinical trials. However, it is not yet clear if
and how the natural history of heart failure in the
absence of LVSD, probably a heterogeneous group
of conditions, can be favourably modified. Future
analyses will provide data on the prevalence
of cardiac dyssynchrony, another potentially
important target for treatment.17,25
The survey highlights the utility of echocardio-
graphic investigation of patients with suspected
heart failure. Echocardiography proved to be useful
in detecting valve disease and pulmonary hyperten-
sion, both potential targets for novel drugs, devices
and interventions, as well as in identifying LVSD.
Unfortunately, LV diastolic function was not re-
ported in the majority of patients. This reflects
uncertainty over diagnostic guidelines for diastolic
heart failure, especially those that depend upon
Doppler assessments in a population with such a
high prevalence of atrial arrhythmias.26,27 Although
the accuracy of LVEF measured by echocardiogra-
phy is controversial, growing expertise and techno-
logical refinements are likely to increase the utility
of echo in the future.
Heart failure is increasingly recognised as a sys-
temic disease associated with cardiac dysfunction.
Anaemia, renal dysfunction and diabetes were
once considered only as conditions that caused or
exacerbated heart failure, but are now recognised
often to be a consequence of heart failure and a
potential target for treatment. The survey shows
that a large proportion of patients are affected by
these conditions, representing a sizeable target for
therapy. Other targets, such as hypertension that
persists despite the development of and treatment
for heart failure may also be an appropriate target
for therapy.
Natural history of heart failure
A high short-term mortality was observed in this
study, virtually identical to that observed in epi-
demiological studies and other hospital discharge
surveys, and considerably higher than in most clini-
cal trials. The high rate of early readmission is also
consistent with previous studies in the UK and
US.3,28,29 Unfortunately, the sort of patients
identified by simple clinical means in this survey
are often excluded from clinical trials, which
require patients to be clinically stable at entry.
These stability criteria need to be reconsidered.
This survey suggests much more uniformity in the
average duration of hospital admission between
countries than has been suggested previously al-
though marked variability exists between individual
patients. This may reflect progress towards an
international standard of care. Nonetheless, the
duration and frequency of hospitalisation continue
to place a high demand on health care resources,
human and financial. Both the length and frequency
of admission are likely to increase as the population
ages and cognitive function declines.
Despite the high mortality and high rates of
readmission, the majority of patients who returned
for interview had few or no symptoms of heart
failure. This may reflect some patient self-
selection, as only about half of surviving patients
attended the interview and it is possible that
patients with more severe heart failure did not.
However, the results suggest that a substantial
number of patients with a recent heart failure
associated admission do not have persisting, severe
symptoms. This could reflect the efficacy of
therapy but also suggests that heart failure may
follow a much more fluctuating or paroxysmal
course than has previously been recognised. This
has important implications for the conduct of
future clinical trials.
Provision of services
The survey highlights the fact that most patients
with heart failure have several cardiovascular and
non-cardiovascular problems in addition to heart
failure. Many patients are old and/or frail. Accord-
ingly, the optimal management of patients with
suspected heart failure is likely to be complex and
requires a multidisciplinary approach. Given the
large number of patients who already occupy hos-
pital beds and the opportunity that hospitalisation
provides to complete key investigations and insti-
tute a long-term management plan, it would seem
appropriate for most hospitals to reorientate some
existing space and resources to the care of patients
with heart failure. Proper discharge planning
through such units may greatly reduce readmis-
sions. Given the minimal cost implications of such
restructuring of health care delivery, the likelihood
of patient benefit and the existing evidence from
randomised controlled trials, the widespread
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development of such units seems justified. Unfor-
tunately, few hospitals in this survey, and probably
less in centres not involved, have units dedicated to
the management of heart failure.
Limitations
One of the main purposes of the survey was to
quantify and describe the uncertainty surrounding a
diagnosis of heart failure. The lack of a precise,
universal definition of heart failure makes the study
of its epidemiology difficult and open to many
criticisms. It was not the objective of this survey to
restrict enrolment to the narrowly defined popula-
tion of heart failure usually included in clinical
trials but rather to include a broad range of
patients, including those in whom the diagnosis is
uncertain, reflecting the current reality of clinical
practice rather than trials.
This survey is likely to reflect better practice
than is actually the case and will have underesti-
mated true hospital heart failure-related activity
for a variety of reasons. We may have selected
hospitals with better than average practice. No
infrastructure existed to support the conduct of
this survey when it was initiated. Consequently, the
survey relied on centres to volunteer their support.
This almost certainly biased the study towards
larger centres, which could support research staff
with a good command of English, the language used
for international communication in this study. How-
ever, the screening process, enrolment of consecu-
tive patients, the pairing of large centres with
smaller community hospitals and the large
population recruited over a short period will all
have helped ensure that the population included
is much more representative of clinical practice
in Europe than any other survey conducted so
far. More than 70% of hospitals also served as
community hospitals. The effect that the type
of hospital enrolling patients had on patient
characteristics will be the subject of several future
analyses.
Unlike myocardial infarction and stroke, heart
failure is usually not a discrete, easily identifiable
event with patient-care restricted to specialised
hospital units. The lack of any proper focus for the
care of patients with heart failure in most hospitals
led to the need for a screening procedure to try and
obtain a representative and comprehensive sample
of patients with heart failure. This step is a key
element of the survey that bridges the gaps
between epidemiological studies, hospital dis-
charge statistics and clinical trials. However, in
order to make the study feasible within the avail-
able resources, we excluded general surgical and
other specialists wards from this survey. Although
heart failure will not be the reason for hospitalis-
ation in the majority of these patients, the preva-
lence of heart failure as an incidental finding
appears to be common among such patients.30
These patients may be even less likely to have
appropriate investigation and treatment. Twenty-
three percent of all deaths and discharges were
enrolled with suspected heart failure, 83% of whom
already carried a diagnosis of heart failure, from
the screened population, a higher than expected
proportion, suggesting that some pre-selection may
have occurred in some countries. This is further
supported by the lower than expected average age
of patients in some countries based on other
data.31,32
Undue emphasis should not be placed on
occasional differences between countries in terms
of mean age, gender and the apparent cause of
heart failure, as these may reflect the practice by a
particular hospital or physician. Also, all centres
will not have applied the protocol in exactly the
same way, a problem with all surveys and clinical
trials. However, overall, the lack of difference
between countries, especially those with larger
samples, was more remarkable than any difference
observed.
Conclusions
The EuroHeart Failure survey provides a large and
detailed set of data on patients with known or
suspected heart failure with a great variety of
underlying pathophysiologies and concomitant
diagnoses. The patients' profiles and their
prognosis are consistent with those in epidemiologi-
cal studies,33,34 are similar to those of patients in
primary care,32 and appear representative of heart
failure in clinical practice. Patients recruited into
the clinical trials reported so far form only a subset
of these patients. Further analyses of this dataset
should help compare and contrast the nature and
diagnosis of heart failure in clinical practice and
clinical trials, identify new targets for therapy and
help plan services to care for the needs of patients
with heart failure.
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